Medpace Holdings, Inc. $MEDP Shares Bought by Cetera Investment Advisers

Cetera Investment Advisers raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,337 shares of the company’s stock after purchasing an additional 323 shares during the period. Cetera Investment Advisers’ holdings in Medpace were worth $3,872,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in MEDP. Private Advisor Group LLC grew its stake in Medpace by 12.3% during the 1st quarter. Private Advisor Group LLC now owns 2,502 shares of the company’s stock worth $762,000 after buying an additional 275 shares during the last quarter. Assetmark Inc. raised its stake in Medpace by 24.9% in the first quarter. Assetmark Inc. now owns 216 shares of the company’s stock valued at $66,000 after buying an additional 43 shares during the last quarter. HB Wealth Management LLC acquired a new stake in Medpace in the first quarter worth about $256,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Medpace by 4.9% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,046 shares of the company’s stock worth $2,147,000 after acquiring an additional 326 shares in the last quarter. Finally, LPL Financial LLC grew its stake in shares of Medpace by 2.3% during the first quarter. LPL Financial LLC now owns 18,374 shares of the company’s stock worth $5,469,000 after acquiring an additional 414 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling

In other news, Director Robert O. Kraft sold 6,472 shares of Medpace stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $591.85, for a total transaction of $3,830,453.20. Following the sale, the director owned 833 shares of the company’s stock, valued at approximately $493,011.05. The trade was a 88.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO August J. Troendle sold 21,858 shares of the stock in a transaction on Friday, November 21st. The stock was sold at an average price of $592.18, for a total value of $12,943,870.44. Following the transaction, the chief executive officer owned 833,627 shares of the company’s stock, valued at approximately $493,657,236.86. This represents a 2.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 225,546 shares of company stock valued at $128,954,899 over the last 90 days. Insiders own 20.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on MEDP shares. UBS Group lowered shares of Medpace from a “neutral” rating to a “sell” rating and increased their price objective for the company from $300.00 to $305.00 in a research report on Tuesday, July 29th. Barclays raised their price target on shares of Medpace from $425.00 to $485.00 and gave the stock an “underweight” rating in a report on Friday, October 24th. BMO Capital Markets assumed coverage on shares of Medpace in a research note on Thursday, November 13th. They set a “market perform” rating and a $600.00 price objective for the company. Rothschild Redb downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have issued a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $487.18.

Medpace Stock Performance

MEDP opened at $611.81 on Wednesday. The stock has a market capitalization of $17.23 billion, a price-to-earnings ratio of 42.78, a PEG ratio of 2.67 and a beta of 1.42. The company has a fifty day moving average of $554.32 and a two-hundred day moving average of $439.13. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $626.26.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.36. The firm had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company’s revenue for the quarter was up 23.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.